Our Programs

Publications

SP-2577 and Analogs

Proceedings of the National Academy of Sciences

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

Journal of medicinal chemistry

High-throughput virtual screening identifies novel N′-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.

Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells.

Inhibition of LSD1 disrupts global EWS/ETS transcriptional function in Ewing sarcoma.

Prostate cancer and prostatic diseases

Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration-and docetaxel-resistant prostate cancer cells.

LSD1’s Role in Cancer

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

ACS chemical biology

Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and-independent manners.

Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase

Biochemical Journal

GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1

LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting

Biochimica et Biophysica Acta

The histone LSD1 demethylase in stemness and cancer transcription programs

Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells